42 related articles for article (PubMed ID: 38627900)
1. Emerging role of immunogenic cell death in cancer immunotherapy.
Arimoto KI; Miyauchi S; Liu M; Zhang DE
Front Immunol; 2024; 15():1390263. PubMed ID: 38799433
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot.
Han Y; Tian X; Zhai J; Zhang Z
Front Cell Dev Biol; 2024; 12():1363121. PubMed ID: 38774648
[TBL] [Abstract][Full Text] [Related]
3. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.
Pagadala M; Sears TJ; Wu VH; Pérez-Guijarro E; Kim H; Castro A; Talwar JV; Gonzalez-Colin C; Cao S; Schmiedel BJ; Goudarzi S; Kirani D; Au J; Zhang T; Landi T; Salem RM; Morris GP; Harismendy O; Patel SP; Alexandrov LB; Mesirov JP; Zanetti M; Day CP; Fan CC; Thompson WK; Merlino G; Gutkind JS; Vijayanand P; Carter H
Nat Commun; 2023 May; 14(1):2744. PubMed ID: 37173324
[TBL] [Abstract][Full Text] [Related]
4. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
Song Q; Zhou Z; Bai J; Liu N
Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
[TBL] [Abstract][Full Text] [Related]
7. An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status.
Chen L; Wen Y; Xiong J; Chen Y; Chen CB
Biomed Res Int; 2023; 2023():1189022. PubMed ID: 36704723
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.
Liu Z; Liu B; Feng C; Li C; Wang H; Zhang H; Liu P; Li Z; He S; Tu C
Front Immunol; 2022; 13():1071636. PubMed ID: 36569869
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analyses of immunogenic cell death-derived gene signatures: Potential biomarkers for prognosis and immunotherapy.
Han X; Song D; Cui Y; Shi Y; Gu X
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2073. PubMed ID: 38627900
[TBL] [Abstract][Full Text] [Related]
10. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy.
Xu W; Liu W; Yang J; Lu J; Zhang H; Ye D
Immunol Rev; 2024 Jan; 321(1):181-198. PubMed ID: 37403660
[TBL] [Abstract][Full Text] [Related]
11. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy.
Yang S; Sun IC; Hwang HS; Shim MK; Yoon HY; Kim K
J Mater Chem B; 2021 May; 9(19):3983-4001. PubMed ID: 33909000
[TBL] [Abstract][Full Text] [Related]
12. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
